NEW YORK (GenomeWeb) – Genomic testing firm MedGenome launched a new blood-based cancer test last month in India, where the firm is based.

Unlike many of the tests that have gained prominence in the US over the past year, which cover anywhere from tens to close to 100 genes, MedGenome's OncoTrack assay is narrowly focused on hotspots in just four genes, which the company believes are the most actionable for guiding currently available targeted therapies.